Evelo Biosciences, Inc. (EVLO)

Market Cap	19.00 -100.0%
Revenue (ttm)	n/a
Net Income	-82.35M
EPS	-9.65
Shares Out	18.98M
PE Ratio	n/a
Forward PE	n/a
Dividend	n/a
Ex-Dividend Date	n/a

Volume	133
Average Volume	4,279
Open	0.0005
Previous Close	0.0005
Day's Range	0.0005 - 0.0005
52-Week Range	0.0000 - 0.0020
Beta	0.65
RSI	42.90
Earnings Date	Mar 23, 2026

About Evelo Biosciences

Evelo Biosciences, Inc., a clinical-stage biotechnology company, focuses on discovering and developing oral medicines that act on immune cells in the small intestine with systemic effects. It is developing EDP1815, a whole-microbe product candidate, which has completed a Phase 2 trial for the treatment of psoriasis . The company is also developing EDP1867, a non-live pharmaceutical preparation for single strain of Veillonella parvula, which is in Phase 1b clinical trial; EDP2939, an investigational oral biologic for the potential treatment of i...

• Industry: Biotechnology
• Sector: Healthcare
• Founded: 2014
• Employees: 66
• Stock Exchange: OTCMKTS
• Ticker Symbol: EVLO